POLYTHERAPY

MA44110AInactive Publication Date: 2018-10-31NUCANA PLC
0 Cites 0 Cited by

Patent Information

Application Number
MA44110
Authority / Receiving Office
MA · MA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-12-21
Filing Date
2016-12-21
Publication Date
2018-10-31
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer treatments using gemcitabine are limited by resistance mechanisms, such as down-regulation of deoxycytidine kinase and up-regulation of cytidine deaminase, which reduce the drug's effectiveness, and existing chemotherapy regimens for biliary tract cancers have poor prognosis with limited survival rates.

Method used

Combining gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate (NUC-1031) with platinum-based anticancer agents like cisplatin to enhance the intracellular concentration and duration of the active metabolite dFdCTP, overcoming resistance mechanisms and improving treatment efficacy for biliary tract and other cancers.

Benefits of technology

The combination therapy significantly increases the intracellular half-life and concentration of dFdCTP, leading to enhanced therapeutic effects, including improved progression-free survival and tumor response in biliary tract cancers, offering a more effective treatment option than single-agent therapies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention relates to a combination of gemcitabine-[phenyl-benzoxy-l-alaninyl]-phosphate (chemical name: 2'-deoxy-2',2'-difluoro-d-cytidine-5'-o-[phenyl(benzoxy-l-alaninyl)] phosphate) (NUC-1031) and a platinum-based anticancer agent selected from cisplatin, picoplatin, lipoplatin, and triplatin. The combinations are useful in the treatment of cancer, particularly gallbladder and bile duct cancer and bladder cancer.
Need to check novelty before this filing date? Find Prior Art